One-Liner
A consumer app giving step-by-step home-injection runbooks for Alzheimer's drug caregivers, with daily ARIA symptom monitoring checklists and neurologist report generation.
AI Thinking Process
Verb Transplant: SRE runbook (on-call playbook) transplanted to home LEQEMBI IQLIK caregiver: step-by-step injection protocol, ARIA monitoring, neurologist escalation.
G191 fires: pharma-branded patient-support app risk. Eisai/Biogen have BiogenLink for MS — likely extend to LEQEMBI. Independent app may be pre-empted at launch.
WHO: adult-child caregiver of early-Alzheimer patient on subQ monthly regimen. CURRENT: paper leaflet from pharmacy, one pharma video. WHY-SURPRISED: home biologic caregiver runbooks are still 2015-era paper.
Survived at 38%. Biggest worry: Eisai/Biogen branded LEQEMBI patient-support app at launch.
ARIA monitoring requirement cross-verified. BiogenLink (Biogen MS patient support), MyOcrevus (Ocrevus), Complete for Humira (AbbVie) all cross-verified — pharma-launch-app pattern is established across multiple drugs.
FEATURE gate failed. If Eisai/Biogen ships branded LEQEMBI patient-support app at Aug 24 launch (near-certain based on BiogenLink/MyOcrevus/Complete precedent), independent product loses primary acquisition channel. Cannot close acquisition-cost math.
Killed in Pass 2 deepening at FEATURE gate. Pharma-launch-app pre-emption is near-certain. Independent multi-drug pivot drops to 34% (below 35% floor). Kill confirmed.
Kill Reason
FEATURE gate killed it in Pass 2. Every major biologic drug manufacturer launches a branded patient-support app alongside PDUFA approval (BiogenLink for MS, MyOcrevus for Ocrevus, Complete for Humira for arthritis). Eisai/Biogen will almost certainly launch a LEQEMBI patient-support app at the August 24 approval event. An independent app loses the primary acquisition channel — physicians and specialty pharmacies push the branded app — and cannot close the acquisition-cost math against a free branded competitor.
Risk Analysis
Risk analysis available for latest engine ideas.
Loading...
Related ideas you can explore free:
killed: The FDA FAERS database is public and already analyzed by multiple academic and consumer health tools. The product's differentiation would need to be clinical interpretation of adverse events — which requires medical supervision to publish actionable advice without running into FDA's off-label promotion rules. Revenue model is unclear: consumers don't pay for health data tools at sustainable ARPU, and pharma companies would not pay for a tool that highlights their drug's adverse events.
killed: The accuracy cliff is fatal: even with careful 'match not authenticate' framing, a wrong call on pharmaceutical safety has catastrophic liability exposure. Sproxil, the African drug authentication leader, has no LatAm presence — but their natural LatAm expansion would eliminate the market gap in 12-24 months. Consumer freemium unit economics are too weak to sustain the accuracy investment required.
killed: Open-source middleware (HAMi) already provides heterogeneous AI computing virtualization for free. Proprietary play is squeezed between free open-source and vertically integrated hardware vendor ecosystem.